Navigation Links
Osteotech Announces Stock Repurchase Program
Date:12/11/2008

EATONTOWN, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that its Board of Directors has authorized a stock repurchase program under which up to $5.0 million of Osteotech's common stock may be acquired. Stock repurchases may be executed from time to time at current market prices through open-market and privately negotiated transactions in such amounts as management deems appropriate. The final number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements and other market conditions. The repurchase program may be terminated at any time without prior notice.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "The authorization of the stock repurchase program by Osteotech's Board of Directors demonstrates the confidence the Board of Directors has in the long-term prospects of Osteotech. The management team and the Board of Directors feel our shares are currently undervalued and believe the repurchase program is an excellent way to enhance the long-term value of the Company."

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... N.J. , June 1, 2015  Novartis ... clinical study of CTL019, an investigational chimeric antigen ... potential in the treatment of specific types of ... conducted by the University of Pennsylvania,s Perelman School ... refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... 2015   Epic Sciences, Inc. , a private ... to personalize and advance the treatment and management of ... credit under its existing credit facility with Silicon ... available capacity of the facility from $5 million to ... months to April 1, 2019.  The availability of additional ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... a wealth of new information about single-walled carbon nanotubes through ... the American Chemical Society journal ACS Nano features ... Bruce Weisman to understand how the lengths and imperfections of ... light they emit at near-infrared wavelengths. The researchers found ...
... 31, 2012  Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the ... filed a Certificate of Amendment to its Amended and ... split of its common stock which will take effect ... we believe this is an opportune time to effect ...
... Calif., Jan. 31, 2012   Veracyte, Inc ., a ... cytology, today announced the appointment of Mark Spring as ... that Mark Spring has joined the Veracyte team," said ... extensive experience as a CFO and senior finance leader ...
Cached Biology Technology:Perfect nanotubes shine brightest 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 3Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 4Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... grapes slow what,s for many Americans a downhill sequence of ... and type 2 diabetes? Scientists at the University ... effect of grapes in reducing risk factors related to cardiovascular ... due to phytochemicals -- naturally occurring antioxidants that ...
... know that eating a calcium-rich diet is important for ... clearly on display in any elementary school cafeteria where ... icons encouraging children to make sure they drink milk ... children to pay attention to their dairy intake might ...
... Studies led by Stony Brook University professor of chemistry ... time a drug remains bound to its target, or ... agents. Tonge will present these results at ... meeting in a talk titled "Slow Onset Inhibitors of ...
Cached Biology News:Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 2Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 3Study suggests a much earlier onset for bone problems 2Study suggests a much earlier onset for bone problems 3Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy 2
384 Cluster Tube Racks...
Request Info...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... The EC105 power supply is a highly compact, ... A single adjustment knob and one hi-lo range ... 10 volt increments from 20 to 250 volts. ... from indicating output voltage to output current. For ...
Biology Products: